Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock. D. Boral Capital’s target price points to a potential upside of 129.71% from the stock’s previous close.

Other analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Price Performance

Shares of NASDAQ:COYA opened at $6.53 on Thursday. The business has a 50-day moving average of $5.86 and a two-hundred day moving average of $6.40. The firm has a market capitalization of $109.12 million, a PE ratio of -10.05 and a beta of 0.47. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Insider Activity

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the acquisition, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders have bought 9,510 shares of company stock worth $69,615. 9.80% of the stock is owned by company insiders.

Institutional Trading of Coya Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics during the second quarter valued at approximately $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the 3rd quarter worth approximately $169,000. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at $401,000. Finally, Geode Capital Management LLC raised its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.